Introduction
Psoriasis is a chronic and incurable inflammatory skin disease, affecting 2 to 3 percent of the United States population, which may vary in severity from localized to diffuse 
Procedure of Data Collection
Complete history, general physical and dermatological examinations were done for all enrolled patients. For women of reproductive age reproductive history, menstrual history, lactation and pregnancy plan were carefully judged. History and physical findings were recorded in a data sheet. Baseline investigations included complete blood count (total count, differential count of white blood cell), platelet count, Hb%, ESR, serum creatinine, serum alanine transaminase, random blood sugar, serum calcium level, serum albumin, serum total protein and pregnancy test (as required) were done. Finally those patients, who matched the selection criteria and willingly gave their informed consent, were selected for the study. Erythema, induration and scaling were recorded in term of PASI (Psoriasis Area and Severity Index) at baseline, after 4th weeks and 8th weeks of therapy as the tool of main outcome measure. Adverse effects of the drugs among all patients of two groups were noted.
Scoring of Psoriasis
Severity of psoriasis were scored by using Psoriasis area and Severity Index (PASI) formula, in which the body was divided into four areas Head (H), Upper limb (U), Trunk (T) and Lower limb (L). Erythema (E), Induration (I) and Desquamation (D) were measured for each area with a scale ranging zero (none), 1 (mild), 2 (moderate), 3 (severe) and 4 (very severe). Erythema and induration were measured as visual impression and palpation of the lesion in place of ideal chromometer and ultrasound respectively. Body surface was measured with palm of patients, taken as 1% total body surface area. Severity of plaque type psoriasis can be classified according to PASI score. Psoriasis can be defined as severe when PASI score >12, moderate when PASI score 7-12 and mild when PASI score <7.
Percentage of PASI score reduction is used for assessment of the efficacy of drug and prognosis of plaque type psoriasis. The percentage of PASI score reduction can be describe as 4 grades. When PASI reduction <50% it can be defined as minimal response, 50%−<70% as moderate response, 70%−<90 % as very good response and >90% as excellent response.
Intervention
Group A were treated with Calcipotriol (0.005%) twice daily and group B were treated with combination of topical Calcipotriol plus Betamethasone once daily. They were treated for the period of 8 weeks. The results of the cases of both group A and group B were evaluated at the end of 8th week. Patients were examined at baseline, and after 4th week of treatment followed by re-examination at the end of 8th week. The severities of psoriasis were evaluated by a single investigator at the center, using the Psoriasis area and severity Index (PASI).
Laboratory parameters were measured before enrollment in the study and at the end of the follow-up period. Follow-up laboratory investigations were complete blood count (Total and differential count of white blood cell, hemoglobin and ESR, Platelet count, Serum alanine transaminase, serum creatinine, serum calcium level, random blood sugar and serum total protein and serum albumin level. Data analysis was performed by Statistical Package for Social Science (SPSS), version-16. Statistical analysis were done and level of significance were measured by using appropriate procedures like chi square test (χ 2 ), paired and unpaired t-test. Level of significance (p-value) was set at 0.05 and confidence interval at 95%. Regarding the duration of illness, most of the patients suffered 1-5 years in both groups, which were 16 (53.3%) and 20(66.7%) in group A and group B respectively. The mean duration of illness was 5.5±3.7 years in group A and 4.4±3.5 years in group B. There was no statistically significant difference between two groups in terms of age, sex, family history of same disease and duration of illness (p value >0.05). There was statistically significant reduction in PASI score from base line after 8th weeks of treatment in both treatment groups (p < 0.001).
Results

Table-VII:
Comparison of PASI scores before and after treatment in two groups.
*Paired t test was done to measure the level of significance.
Discussion
Our study showed statistically significant reduction in PASI score from base line to 8th week of treatment in both treatment groups (p<0.001). Kragballe conducted a study to investigate the efficacy of different treatment regimens with the two-compound product (Calcipotriol and Betamethasone Dipropionate) and Calcipotriol Ointment. In total, 972 patients with psoriasis vulgaris were randomized to one of three treatment regimens: group 1, the two-compound product once daily for 8 weeks followed by Calcipotriol Ointment once daily for 4 weeks; group 2, the two-compound product once daily for 4 weeks followed by 8 weeks of treatment with Calcipotriol Ointment once daily on weekdays and the two-compound product once daily at weekends; and group 3, Calcipotriol Ointment twice daily for 12 weeks. The efficacy was evaluated by Psoriasis Area and Severity Index (PASI) and investigators' global assessments of disease severity. The primary response criteria were percentage reduction in PASI and proportion of patients with absent/very mild disease according to the investigators' global assessments after 8 weeks of treatment. The mean reduction in PASI from baseline to the end of 8 weeks of treatment was 73.3% for group 1, 68.2% for group 2 and 64.1% for group 3. The proportion of patients with absent/very mild disease at the end of 8 weeks of treatment was 55.3% for group 1, 47.7% for group 2 and 40.7% for group 3. For both primary response criteria, group 1 was statistically superior to group 3 (P < 0.001), whereas group 2 did not differ significantly from group 3. The difference between group 1 and group 2 was statistically significant with regard to PASI but not regarding the proportion of patients with absent/very mild disease. Patients receiving initial therapy with the two-compound product achieved the fastest treatment response, and the maximum treatment effect for these patients was seen after 5 weeks. This effect was maintained with continued treatment with the two-compound product for up to 8 weeks. After 12 weeks of treatment, no significant differences were seen between the three groups with regard to reduction in PASI, whereas the proportion of patients with absent/very mild disease in group 2 was superior to that in group 3. Patients receiving therapy with the two-compound product experienced fewer lesional/perilesional adverse drug reactions than the Calcipotriol-treated patients (P<0.001): 10.9% in group 1,11.5% in group 2 and 22.3% in group 3.They concluded that two different short-term treatment regimens employing a recently developed two-compound product (Calcipotriol and Betamethasone Dipropionate) provided rapid and marked clinical efficacy and were shown to be safe therapies for psoriasis vulgaris 17 
Conclusion
In the light of the findings of the study we conclude that the combination therapy of Calcipotriol(0.005%) and Betamethasone (0.1%) is more effective than monotherapy calcipotriol(0.005%), therefore it may be recommended that monotherapy can be replaced with once daily Calcipotriol and Betamethasone combination in treating plaque psoriasis. Study with a larger group of patients for longer period may result in superior outcome in clinical practice through improved compliance.
